A qepA8+ Shigella flexneri was cultured from the stool of a traveler returning from India and East Asia. This 20 chromosomally encoded qepA variant, has a six-base insertion, and may have been mobilized as part of a 21 complex IS1-mediated composite transposon including catA1, aadA1, and bla OXA-1 . In laboratory E. coli, qepA8 22
alone only conferred decreased ciprofloxacin susceptibility; however, it may work in combination with 23 additional mechanisms to confer clinical resistance. 24 25 Shigellosis is an important public health problem. Shigella causes an estimated 500,000 cases of diarrhea in the 26 United States annually (1). In both the United States and Europe, children in daycare centers, travelers to 27 developing countries, and men who have sex with men are most often infected. Antibiotics are used to treat 28 severe infection and to shorten the duration of illness (2). Although not usually necessary, ciprofloxacin (for 29 adults) and azithromycin (for children) are the preferred treatment (3, 4) . Increasing resistance poses a major 30 therapeutic challenge (5). In Enterobacteriaceae, quinolone resistance is largely attributed to mutations in the 31 quinolone resistance-determining regions (QRDR) of gyrA, gyrB, parC, and parE, and plasmid-mediated 32 quinolone resistance (PMQR) determinants (e.g., qnr genes, aac(6')-Ib-cr, or qepA). The qepA gene encodes a 14-33 transmembrane-segment efflux pump of the major facilitator superfamily. The functionality of four variants, 34 designated qepA1-4, have been described in literature (6-10); however, other qepA sequence variations were 35 recently designated qepA5-10, despite having unknown functionality against quinolones (11). Here, we describe 36 a qepA8 detected in Shigella flexneri from a patient in the United States. 37
In the United States, public health laboratories submit every twentieth Shigella isolate to the Centers for Disease 38
Control and Prevention (CDC) National Antimicrobial Resistance Monitoring System (12). In 2016, 544 Shigella 39 isolates were genome sequenced and phenotypically tested against 14 antibiotics by broth microdilution 40 (Sensititre™; Table 1 ). During routine screening, a single ciprofloxacin-resistant Shigella flexneri strain had a 41 qepA variant with a six base insertion at position 1,065. The S. flexneri was cultured from the stool of a 69-year-42 old man in 2016. The patient reported spending several months traveling in Asia (Taiwan, Thailand, Laos, 43 Cambodia, and India) and sought treatment at a local hospital in India after developing abdominal cramping and 44 bloody diarrhea. According to the patient, diarrheagenic Escherichia coli was cultured from his stool and was 45 prescribed ciprofloxacin in India, but his diarrhea worsened and he sought medical care in the United States 2-3 46 weeks later. However, in the United States, Shigella was isolated from his stool and a five-day course of 47 ciprofloxacin was again prescribed. The patient was not hospitalized and recovered. Due to the close genetic 48 relationship between E. coli and Shigella, it is possible the patient had a single prolonged infection of Shigella, 49 both ciprofloxacin treatments were ineffective, and the Shigella infection resolved on its own after >4 weeks. 50
Genomic DNA was extracted using the Wizard Genomic DNA Purification (Promega Corporation, Madison, WI, 51 USA). Libraries sequenced on the Illumina HiSeq platform were prepared using the NEBNext Ultra DNA library 52 prep kit (New England Biolabs, Ipswich, MA). Libraries sequenced on the Pacific Biosciences RSII system were 53 generated using standard library protocols of the DNA template preparation kit (PacBio, Menlo Park, CA, USA). 54
Sequence reads were filtered and assembled de novo using the Hierarchical Genome Assembly Process (HGAP) 55 v3 (13) and circularized using Circlator v1.5.5 (14). PacBio sequences were corrected using Illumina reads. 56
Annotation was performed using Prokka (v1.13.3 (15)) and Galileo AMR (16) before submission to NCBI 57 (2016AM-0877; Accession no. CP033510.1 and CP033511.1). Resistance genes were identified using assembly-58 based methods with the ResFinder database (https://github.com/phac-nml/staramr) and QRDR mutations by 59 direct sequence comparison. 60
In 2016AM-0877, qepA8 was chromosomally located and may have been captured/mobilized as part of an IS1-61 mediated composite transposon flanked by direct repeats (Figure 1 ), which also includes catA1 (V00622), aadA1 62 (JX185132), bla OXA-1 (J02967), and a truncated dfrB4 gene. In addition, QRDR mutations were observed in gyrA 63 (Ser83Leu and Asp87Asn) and parC (Ser80Ile). Additional resistance genes (outside the qepA-transposon) were 64 also identified, including two aadA1 (JQ480156; JX185132), dfrA1 (X00926), bla OXA-1 (J02967), and two tet(B) 65 (AF326777). Phenotypic resistance was observed to amoxicillin-clavulanic acid, ampicillin, chloramphenicol, 66 ciprofloxacin, nalidixic acid, streptomycin, and tetracycline (Table 1) available long-reads, one had a 149,768-bp plasmid-herein referred to as pM216_mF (Genbank LC492469)-73 which carried qepA8 in a complex composite transposon that appeared to be highly related (<10 single-74 nucleotide polymorphisms in the shared region [gray in Figure 1 ]) to that observed in 2016AM-0877. The 75 similarities suggest that a pM216_mF-like plasmid was likely the source of the context observed in the 76 chromosome of 2016AM-0877, which may have initially been mobilized by IS1. 77
Since qepA8 was chromosomally-encoded in 2016AM-0877 alongside QRDR mutations, a transformation 78 experiment was used to assess functionality of plasmid-encoded qepA8 in M216. Briefly, plasmid DNA was 79 extracted from M216 and introduced into a TOP10 E. coli strain by electroporation. Transformants were selected 80 on LB plates containing 30 μg/mL of chloramphenicol. Plasmid size and qepA presence was confirmed by S1-81 PFGE (17) and PCR (5'-ATGTCCGCCACGCTCCACGAC-3', 5'-TCAACCAGATGCGAGCGCTG-3'), respectively. Broth 82 microdilution for the TOP10 transformants compared with untransformed E. coli TOP10 (performed in triplicate) 83 found an at least eight-fold and a two-fold increase in MIC was observed for ciprofloxacin and levofloxacin 84 (Table 1) , respectively; however, MIC values remained significantly below clinical breakpoints (19) . 85
In conclusion, we describe a novel qepA variant that mediates reduced susceptibility to ciprofloxacin. Although 86 the ciprofloxacin MIC did not increase above the resistance breakpoint, PMQR genes may complement other 87 quinolone resistance mechanisms to reach clinical resistance levels, and may additionally facilitate the selection 88 of higher-level resistance by increasing the mutant prevention concentration (20). To our knowledge, this is the 89 first report on the genetic context and functionality of qepA8. Publicly available sequences indicate qepA8 has 90 also been reported in E. coli/Shigella outside of the United States and was present as early as 2010. As public 91 health labs transition into this era of whole genome sequencing, there will be increasing opportunities to 92 investigate novel variants of resistance genes and determine the extent to which they confer antimicrobial 93 resistance. 94
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